Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.

摘要: Glioblastoma is the most frequent primary neoplasm of central nervous system and still suffers from very poor therapeutic impact. No clear improvements over current standard care have been made in last decade. For other cancers, but also for brain metastasis, which harbors a distinct biology glioblastoma, immunotherapy has already proven its efficacy. Efforts pursued to allow glioblastoma patients benefit these new approaches, road long broad application. Here, we aim review key immune related characteristics, immunotherapeutic strategies being explored, their potential caveats, future directions.